Description
Cagrilintide is a long-acting, fatty-acid-modified analogue of the pancreatic hormone amylin, developed by Novo Nordisk and best known as the “Cagri” in CagriSema. Pure Peptides Canada supplies it only as a lyophilized laboratory reagent, in 5 and 10 mg vials, with an independent Janoshik HPLC and mass-spectrometry report and tracked shipping from inside Canada. It is not an approved medicine and is not for human use.
Cagrilintide at a glance
- What it is: a 37-residue amylin analogue with a fatty-acid side chain, engineered to resist the clumping that makes natural amylin unusable as a drug.
- What researchers study: amylin- and calcitonin-receptor pharmacology, peptide aggregation, and how amylin signalling combines with the GLP-1 pathway.
- Evidence level: cell, animal and controlled human trials, mostly testing the CagriSema combination with semaglutide.
- Regulatory status: not approved anywhere, including Canada.
- Supplied as: sealed lyophilized powder, 5 or 10 mg, single vial or box of 10.
- Delivery: ships from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299.
Regulatory status: cagrilintide is an investigational compound and is not authorized in Canada. The research reagent sold here is not CagriSema or any approved drug. We sell it strictly as a laboratory reagent for in-vitro research to qualified research buyers, and we do not provide dosing, administration or medical information.
Cagrilintide
Long-acting amylin analogue · Novo Nordisk · the cagrilintide half of CagriSema
- C20
- K
- C
- N
- T
- A
- T
- C
- A
- T
- Q
- R
- L
- A
- E
- F
- L
- R
- H
- S
- S
- N
- N
- F
- G
- P
- I
- L
- P
- P
- T
- N
- V
- G
- S
- N
- T
- P
Blue: the six positions changed from human amylin (14, 17, 25, 28, 29 and 37). Dashed: the two cysteines joined by a disulfide bridge. C20: the eicosanedioic-acid side chain attached at the N-terminus through γ-glutamate. The C-terminus is amidated.
- Length
- 37 amino acids, one disulfide bond, N-terminal fatty diacid
- Molecular formula
- C194H312N54O59S2
- Molecular weight
- ≈ 4409.0 g/mol
- CAS number
- 1415456-99-3
- Developer
- Novo Nordisk
- Form
- Lyophilized powder, sealed vial
- Sizes
- 5 or 10 mg (single or box of 10)
- SKU
- PP-CAGRILINTIDE
Where the evidence stands
- Cell studies
- Animal models
- Controlled human trials
- Approved medicine
Most large trials test cagrilintide combined with semaglutide as CagriSema, which was filed with the US FDA in December 2025 and was not approved as of September 2026. Cagrilintide is not an approved medicine.
What is cagrilintide?
Amylin is a 37-amino-acid hormone that pancreatic beta cells release together with insulin. It slows stomach emptying, restrains glucagon after meals and signals fullness through the brainstem. Natural human amylin readily forms amyloid fibrils, which made it unusable as a drug, and the first workaround, pramlintide, was short-acting.
Novo Nordisk designed cagrilintide to solve both problems. Proline substitutions at positions 25, 28 and 29, the same changes used in pramlintide, reduce fibrillation; further changes at positions 14, 17 and 37 were introduced during its development; and an eicosanedioic-acid side chain lets the peptide bind albumin and stay in circulation far longer. It activates amylin receptors (the calcitonin receptor paired with RAMP1, RAMP2 or RAMP3) and the calcitonin receptor on its own. A Phase 2 trial of cagrilintide alone, led from the University of Calgary, was published in The Lancet in 2021, and the REDEFINE programme then tested it with semaglutide. Our cagrilintide research guide summarizes those trials with sources.
What cagrilintide research looks at
- Receptor pharmacology: activity at AMY1, AMY2 and AMY3 receptors compared with the calcitonin receptor alone.
- Aggregation and fibrillation: how the engineered analogue behaves against human amylin in fibril-formation assays.
- Amylin and GLP-1 interplay: combination designs and comparisons with GLP-1-pathway compounds such as retatrutide and mazdutide.
- Analytical methods: HPLC and mass-spectrometry methods for lipidated, aggregation-prone peptides.
Ordering cagrilintide for laboratory research
Check the report names cagrilintide and shows a mass near 4409 Da.
See lab resultsCagrilintide FAQ
Where can I buy cagrilintide in Canada?
Pure Peptides Canada supplies cagrilintide only as a lyophilized laboratory reagent, in 5 and 10 mg vials, shipped from inside Canada by tracked Xpresspost in 3–7 days ($25 CAD), or free in 4–12 days on orders over $299. It is not CagriSema or any medicine, and it is not sold for human use.
Is cagrilintide a GLP-1 agonist?
No. Cagrilintide acts on amylin receptors and the calcitonin receptor, not the GLP-1 receptor. It is often discussed with GLP-1 compounds because it is paired with semaglutide in CagriSema.
Is cagrilintide approved in Canada?
No. Cagrilintide is not approved as a medicine anywhere, including Canada. The CagriSema combination was filed with the US FDA in December 2025 and was not approved as of September 2026.
How do I confirm the identity of a cagrilintide batch?
Check that the mass-spectrometry result matches cagrilintide’s theoretical mass, about 4409 Da, that the HPLC method suits lipidated peptides, and that the lot number matches your vial. Our COA guide and HPLC guide explain what to look for.
Can cagrilintide be used in people or animals?
No. This product is for in-vitro laboratory research only and is not a drug, supplement or food. We do not provide dosing or administration information.
For laboratory research use only. Not a drug, supplement, food or cosmetic, not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Reviews
There are no reviews yet.